This inventor holds 2 USPTO granted patents. Top assignees: The United States of America, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 1999-2005.
Company Filing History:
1 out of 255 
1 out of 3,688 
Years Active: 1999-2005
Title: Mark Hamblin: Innovator in Serotonin Receptor Research
Introduction
Mark Hamblin is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of serotonin receptor research. With a total of 2 patents, his work has advanced our understanding of these critical proteins.
Latest Patents
Hamblin's latest patents include the St-B17 serotonin receptor and the PCT-65 serotonin receptor. The St-B17 serotonin receptor patent details the cloning and characterization of genes encoding the St-B17 serotonin receptor protein from rat striatum mRNA and a human genomic library. This receptor exhibits nucleotide and amino acid homology with previously described 5-HT genes and is capable of binding ligands known to interact with serotonin receptors. Furthermore, the levels of intracellular cAMP in cells transfected with the receptor gene respond in a dose-dependent manner to the introduction of serotonin in the media.
Career Highlights
Throughout his career, Hamblin has worked with various organizations, including the United States of America and the Department of Health and Human Services. His research has been pivotal in the exploration of serotonin receptors and their implications in various biological processes.
Collaborations
Hamblin has collaborated with esteemed colleagues such as David Robert Sibley and Frederick J Monsma, Jr. Their combined expertise has contributed to the advancement of serotonin receptor research.
Conclusion
Mark Hamblin's innovative work in serotonin receptor research has led to significant advancements in the field. His patents reflect a deep understanding of molecular biology and its applications in health and medicine.